Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

Kooij, Monique K. Van der; Joosse, Arjen; Speetjens, Frank M.; Hospers, Geke A.P.; Bisschop, Kees; Groot, Jan Willem B. de; Koornstra, Rutger H.T.; Blank, Christian U.

doi:10.1080/0284186x.2016.1260773

Cited by 44 publications

(37 citation statements)

References 14 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from the Netherlands by Van der Kooij et al indicates limited activity of these two antibodies used as monotherapy. 100 These results are in concordance with the ones obtained in another study by Algazi et al In these cases the median PFS obtained was 2.3-2.6 months, respectively. In contrast, more favorable results were obtained by Kottschade et al…”

Section: Immunotherapysupporting

confidence: 92%

Recent advances in uveal melanoma treatment

Álvarez‐Rodríguez

Latorre

Posch

et al. 2017

Medicinal Research Reviews

View full text Add to dashboard Cite

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Recent advances in the understanding of molecular characteristics helped to determine which tumors are most likely to progress. About 50% of patients carrying genetic alterations such as chromosomal aberrations and mutations are at significant risk for metastatic disease of which the majority will succumb to UM within few months. Currently, there is no effective treatment for metastatic uveal melanoma, and we hope this review will encourage researchers and clinicians to work to find a better standard of care.In this article we provide a comprehensive overview of the molecular framework of UM, highlighting the most common mutations involved in this kind of cancer. It also covers the most recent treatments from basic research to clinical trials, including small molecules, nucleic acids or immunotherapy, among others. It is intended to serve as a key reference for clinicians and researchers working in this field.

show abstract

Section: Immunotherapysupporting

confidence: 92%

Recent advances in uveal melanoma treatment

Álvarez‐Rodríguez

Latorre

Posch

et al. 2017

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…The blockade of immune checkpoints has been the most promising approach to activating antitumor immunity. A tumor immunotherapy treatment strategy using a combined PD-1/PD-L1 antibody has entered the stage of clinical trials and shown good performance [66, 67]. …”

Section: Discussionmentioning

confidence: 99%

Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma

et al. 2017

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) carries a high potential for metastasis and immune escape, with a great risk of relapse after primary treatment. Through analysis of whole genome expression profiling data in NPC samples, we found that the expression of a long non-coding RNA (lncRNA), actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1), is significantly correlated with the immune escape marker programmed death 1 (PD-1). We therefore assessed the expression of AFAP1-AS1 and PD-1 in a cohort of 96 paraffin-embedded NPC samples and confirmed that AFAP1-AS1 and PD-1 are co-expressed in infiltrating lymphocytes in NPC tissue. Moreover, patients with high expression of AFAP1-AS1 or PD-1 in infiltrating lymphocytes were more prone to distant metastasis, and NPC patients with positive expression of both AFAP1-AS1 and PD-1 had the poorest prognosis. This study suggests that AFAP1-AS1 and PD-1 may be potential therapeutic targets in NPC and that patients with co-expression of AFAP1-AS1 and PD-1 may be ideal candidates for future clinical trials of anti-PD-1 immune therapy.

show abstract

“…Three other reports retrospectively evaluated the efficacy of nivolumab in a rather low number of patients [118][119][120]. ORR ranged from 0% [118] up to 25% [119]. The median PFS was not reported in [119] and was 2.3 months in the other studies, and the median OS ranged from 9.6 months [118] to about 14 months [120].…”

Section: Nivolumabmentioning

confidence: 99%

“…The PD-1 blocking antibody nivolumab was evaluated in one prospective phase II trial [117] and three retrospective analyses [118][119][120].…”

Section: Nivolumabmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Immune Checkpoint Blockade in Uveal Melanoma

Wessely

Steeb

Erdmann

et al. 2020

IJMS

View full text Add to dashboard Cite

Uveal melanoma (UM) represents the most common intraocular malignancy in adults and accounts for about 5% of all melanomas. Primary disease can be effectively controlled by several local therapy options, but UM has a high potential for metastatic spread, especially to the liver. Despite its clinical and genetic heterogeneity, therapy of metastatic UM has largely been adopted from cutaneous melanoma (CM) with discouraging results until now. The introduction of antibodies targeting CTLA-4 and PD-1 for immune checkpoint blockade (ICB) has revolutionized the field of cancer therapy and has achieved pioneering results in metastatic CM. Thus, expectations were high that patients with metastatic UM would also benefit from these new therapy options. This review provides a comprehensive and up-to-date overview on the role of ICB in UM. We give a summary of UM biology, its clinical features, and how it differs from CM. The results of several studies that have been investigating ICB in metastatic UM are presented. We discuss possible reasons for the lack of efficacy of ICB in UM compared to CM, highlight the pitfalls of ICB in this cancer entity, and explain why other immune-modulating therapies could still be an option for future UM therapies.

show abstract

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

Cited by 44 publications

References 14 publications

Recent advances in uveal melanoma treatment

Recent advances in uveal melanoma treatment

Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma

The Role of Immune Checkpoint Blockade in Uveal Melanoma

Contact Info

Product

Resources

About